By Fineline Cube 
Dutch device giant Royal Philips (NYSE: PHG) and China-based Suzhou Peixin Technology Co., Ltd. late last month signed a memorandum of understanding to establish an in-depth collaboration in developing an AI-powered interventional therapy ecosystem platform. This partnership aims to advance precision treatment, optimize clinical pathways, and enhance overall quality of care in structural heart disease interventions.
Collaboration Objectives
The collaboration focuses on developing an integrated AI-powered platform to support structural heart disease interventions. This includes ecosystem development, solution promotion, joint marketing, and intraoperative image fusion. The platform is designed to provide clinicians with an optimized, integrated workflow, improving treatment efficiency and quality.
Benefits for Clinicians and Patients
The partnership aims to reduce the learning curve for physicians and the burden on patients by streamlining the intervention process. By enhancing the overall quality of care, the initiative is expected to create better conditions for patient recovery and improve outcomes in structural heart disease interventions.
Future Plans
The two companies initiated their AI platform launch plan at CMEF in April this year and will continue to drive the growth of the AI interventional platform ecosystem moving forward. This ongoing collaboration underscores their commitment to advancing medical technology and improving patient care through innovative solutions.-Fineline Info & Tech